Association of Aggresomes with Survival Outcomes in Pediatric Medulloblastoma.
Adolescent
Biomarkers, Tumor
/ genetics
Child
Child, Preschool
Disease-Free Survival
Female
Hedgehog Proteins
/ genetics
Humans
Male
Medulloblastoma
/ classification
Pediatrics
Prognosis
Protein Aggregates
/ genetics
Proteostasis Deficiencies
/ classification
Retrospective Studies
Risk Factors
Wnt Proteins
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 08 2019
30 08 2019
Historique:
received:
13
03
2019
accepted:
14
08
2019
entrez:
1
9
2019
pubmed:
1
9
2019
medline:
27
10
2020
Statut:
epublish
Résumé
Aggresomes are inclusion bodies for misfolded/aggregated proteins. Despite the role of misfolded/aggregated proteins in neurological disorders, their role in cancer pathogenesis is poorly defined. In the current study we aimed to investigate whether aggresomes-positivity could be used to improve the disease subclassification and prognosis prediction of pediatric medulloblastoma. Ninety three pediatric medulloblastoma tumor samples were retrospectively stratified into three molecular subgroups; WNT, SHH and non-WNT/non-SHH, using immunohistochemistry and Multiplex Ligation Probe Amplification. Formation of aggresomes were detected using immunohistochemistry. Overall survival (OS) and event-free survival (EFS) were determined according to risk stratification criteria. Multivariate Cox regression analyses were carried out to exclude confounders. Aggresomes formation was detected in 63.4% (n = 59/93) of samples. Aggresomes were non-randomly distributed among different molecular subgroups (P = 0.00002). Multivariate Cox model identified aggresomes' percentage at ≥20% to be significantly correlated with patient outcome in both OS (HR = 3.419; 95% CI, 1.30-8.93; P = 0.01) and EFS (HR = 3; 95% CI, 1.19-7.53; P = 0.02). The presence of aggresomes in ≥20% of the tumor identified poor responders in standard risk patients; OS (P = 0.02) and EFS (P = 0.06), and significantly correlated with poor outcome in non-WNT/non-SHH molecular subgroup; OS (P = 0.0002) and EFS (P = 0.0004).
Identifiants
pubmed: 31471537
doi: 10.1038/s41598-019-49027-x
pii: 10.1038/s41598-019-49027-x
pmc: PMC6717208
doi:
Substances chimiques
Biomarkers, Tumor
0
Hedgehog Proteins
0
Protein Aggregates
0
SHH protein, human
0
Wnt Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12605Références
J Biol Chem. 2005 Dec 2;280(48):40282-92
pubmed: 16192271
Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):687-697
pubmed: 27238212
Sci Rep. 2017 Aug 14;7(1):8022
pubmed: 28808307
J Cell Sci. 2008 Dec 15;121(Pt 24):4079-88
pubmed: 19033385
Autophagy. 2018;14(6):1079-1081
pubmed: 28837386
Cancer Metastasis Rev. 2017 Dec;36(4):635-653
pubmed: 29134486
Cancer Res. 2006 Apr 1;66(7):3773-81
pubmed: 16585204
Int J Oncol. 2015 Feb;46(2):474-86
pubmed: 25422130
Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a004374
pubmed: 21746797
J Clin Oncol. 2003 Apr 15;21(8):1581-91
pubmed: 12697884
Cancer Treat Rev. 2009 Feb;35(1):79-96
pubmed: 18976866
Neuropathol Appl Neurobiol. 2015 Feb;41(2):135-44
pubmed: 24894640
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
Mol Genet Metab. 2008 Jul;94(3):283-6
pubmed: 18472289
Curr Med Chem. 2008;15(1):47-60
pubmed: 18220762
Autophagy. 2008 Jan;4(1):85-7
pubmed: 17957134
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Hum Mol Genet. 2017 Aug 15;26(16):3130-3143
pubmed: 28535259
Cell. 2003 Dec 12;115(6):727-38
pubmed: 14675537
Science. 1999 Dec 3;286(5446):1888-93
pubmed: 10583944
Biol Open. 2014 May 02;3(6):418-30
pubmed: 24795145
Acta Neuropathol. 2011 Mar;121(3):381-96
pubmed: 21267586
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Biochim Biophys Acta. 2014 Jan;1843(1):13-25
pubmed: 23994620
Trends Cell Biol. 2000 Dec;10(12):524-30
pubmed: 11121744
Neurol India. 2006 Mar;54(1):16-23
pubmed: 16679637
J Biotechnol. 2015 Jul 10;205:3-13
pubmed: 25592050
J Cell Mol Med. 2010 Mar;14(3):457-87
pubmed: 20070435
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Cancer Res. 2010 Nov 15;70(22):9265-76
pubmed: 21045142
Mol Cell. 2005 Feb 4;17(3):351-65
pubmed: 15694337
J Neurooncol. 2018 Jun;138(2):231-240
pubmed: 29427151
Int J Mol Med. 2001 Nov;8(5):573-8
pubmed: 11605030
Asian J Neurosurg. 2015 Jan-Mar;10(1):50
pubmed: 25767583
J Cell Biol. 1998 Dec 28;143(7):1883-98
pubmed: 9864362
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2010 Dec 23;468(7327):1095-9
pubmed: 21150899
J Clin Oncol. 2013 Aug 10;31(23):2936-41
pubmed: 23857975
J Neurosci. 2003 Nov 19;23(33):10672-80
pubmed: 14627652